299 related articles for article (PubMed ID: 35048023)
1. Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer.
Bos T; Ratti JA; Harada H
Front Oral Health; 2021; 2():676643. PubMed ID: 35048023
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Taberna M; Oliva M; Mesía R
Front Oncol; 2019; 9():383. PubMed ID: 31165040
[TBL] [Abstract][Full Text] [Related]
5. Precision Medicine Approaches to Overcome Resistance to Therapy in Head and Neck Cancers.
Ortiz-Cuaran S; Bouaoud J; Karabajakian A; Fayette J; Saintigny P
Front Oncol; 2021; 11():614332. PubMed ID: 33718169
[TBL] [Abstract][Full Text] [Related]
6. New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects.
Hu H; Li B; Wang J; Tan Y; Xu M; Xu W; Lu H
Biomed Pharmacother; 2023 Jul; 163():114778. PubMed ID: 37137185
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
9. Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Ghosh S; Shah PA; Johnson FM
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887235
[TBL] [Abstract][Full Text] [Related]
10. Clinical immunotherapeutic approaches for the treatment of head and neck cancer.
Kareemaghay S; Tavassoli M
Int J Oral Maxillofac Surg; 2019 Apr; 48(4):419-436. PubMed ID: 30401512
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
12. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
[TBL] [Abstract][Full Text] [Related]
13. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming of Energy Metabolism in Response to Radiotherapy in Head and Neck Squamous Cell Carcinoma.
Cruz-Gregorio A; Martínez-Ramírez I; Pedraza-Chaverri J; Lizano M
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764513
[TBL] [Abstract][Full Text] [Related]
15. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
16. Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance.
Muraro E; Fanetti G; Lupato V; Giacomarra V; Steffan A; Gobitti C; Vaccher E; Franchin G
Crit Rev Oncol Hematol; 2021 Aug; 164():103424. PubMed ID: 34245856
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas.
Griso AB; Acero-Riaguas L; Castelo B; Cebrián-Carretero JL; Sastre-Perona A
Cells; 2022 Feb; 11(3):. PubMed ID: 35159370
[TBL] [Abstract][Full Text] [Related]
18. Regulation of NFκB Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?
Morgan EL; Chen Z; Van Waes C
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33036368
[TBL] [Abstract][Full Text] [Related]
19. New treatment strategies for HPV-positive head and neck cancer.
Kofler B; Laban S; Busch CJ; Lörincz B; Knecht R
Eur Arch Otorhinolaryngol; 2014 Jul; 271(7):1861-7. PubMed ID: 23934317
[TBL] [Abstract][Full Text] [Related]
20. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
